Phase 1/2: TroFuse-01A Trial Tests a TROP2-Targeted ADC in Metastatic Prostate Cancer

A newly registered Phase 1/2 clinical trial will investigate sacituzumab tirumotecan (MK-2870), an experimental antibody-drug conjugate (ADC), as a potential treatment for metastatic castration-resistant prostate cancer (mCRPC).

Sacituzumab tirumotecan targets TROP2, a cell-surface protein expressed in several cancer types. The drug combines a TROP2-directed antibody with a cytotoxic payload designed to damage cancer cells after the ADC binds to its target.

The payload is a topoisomerase I inhibitor, a class of compounds that interferes with DNA processing and can cause lethal damage to rapidly dividing cells.

This approach differs from PSMA-targeted therapies, including radioligand treatments such as Pluvicto. Instead of delivering radioactive material to PSMA-expressing cells, sacituzumab tirumotecan uses an antibody to transport a chemotherapy-like payload to cells expressing TROP2.

The trial will evaluate sacituzumab tirumotecan alone at two dose levels and in combination with opevesostat, an experimental oral inhibitor of steroid hormone synthesis.

The study also includes a docetaxel-based comparator arm, allowing researchers to evaluate the experimental treatments against an established chemotherapy option.

TroFuse-01A is particularly noteworthy because it adds another molecular target to the expanding ADC landscape in advanced prostate cancer. Alongside PSMA- and B7-H3-directed approaches, TROP2-targeted drug delivery may eventually offer additional treatment opportunities for patients whose disease progresses despite androgen pathway inhibition.

Clinical Trial